Torrey Pines Medicine Shenzhen Ltd. has completed an angel financing round raising tens of millions of RMB. Led by Lotus Lake Ventures, the funding will accelerate IND filing and Phase I trials for TPM004, an ultra-long-acting amylin/calcitonin receptor dual agonist, and advance the company's…
Torrey Pines Medicine Shenzhen Ltd., a biotechnology company focusing on next-generation ultra-long-acting peptide therapeutics for metabolic diseases, has announced the successful completion of an angel financing round. The round raised tens of millions of RMB. Lotus Lake Ventures led the investment, with participation from Stars Capital, Tainuo Capital, Blue Ocean Capital, and renowned entrepreneur Mr. Yousheng Shen. The proceeds will primarily support corporate development, with a specific focus on accelerating the IND filing and Phase I clinical trials for the company's core pipeline asset, TPM004. Additionally, the funds will be used to further refine the proprietary PepTetris ultra-long-acting peptide technology platform, which continuously empowers early-stage R&D pipelines.
Dr. Qingsong Zhu, Co-founder and Chief Executive Officer of Torrey Pines Medicine, expressed gratitude for investor trust and support. He noted that research and development in metabolic diseases is entering a new era, with significant unmet clinical needs remaining in patient compliance, enhanced efficacy, and better overall therapeutic experience. Dr. Zhu stated that the company will continue leveraging its proprietary platform to engineer globally competitive ultra-long-acting peptide therapeutics. The goal is to provide convenient and highly effective long-term management solutions for patients.
Kai Guo, partner at Lotus Lake Ventures, spoke on behalf of the lead investor. Guo said that Lotus Lake Ventures has long tracked global trends in metabolic innovation and firmly believes that ultra-long-acting technology represents a critical frontier for next-generation metabolic therapies. He highlighted that Torrey Pines Medicine combines a highly experienced international leadership team with proprietary platform technologies and a differentiated pipeline addressing significant unmet medical needs. Guo expressed enthusiasm for supporting the company as it advances its lead programs into the clinic and establishes itself as a globally recognized biotechnology company.
Dr. Weijun Shen, Co-founder and Chief Scientific Officer of Torrey Pines Medicine, explained the company's scientific philosophy. He stated that developing truly next-generation peptide therapeutics requires more than simply extending drug half-life. Developing ultra-long-acting peptide medicines necessitates a holistic optimization of molecular design, receptor pharmacology, pharmacokinetics, manufacturability, and clinical translatability. The objective, according to Dr. Shen, is not simply to prolong circulation time, but to engineer molecules that deliver the optimal balance of efficacy, safety, dosing convenience, and developability.
TPM004, the company's lead asset, is a differentiated ultra-long-acting amylin/calcitonin receptor dual agonist. It is being developed for obesity, diabetes, and other metabolic diseases. The PepTetris platform is designed to enable the creation of these ultra-long-acting peptide therapeutics.
Dr. Nieng Yan, President of the Shenzhen Medical Academy of Research and Translation SMART and Director of Shenzhen Bay Laboratory SZBL , congratulated the company on completing its angel financing. Dr. Yan noted that Torrey Pines Medicine is a flagship venture incubated by Shenzhen Bay Laboratory. The company encapsulates the deep integration of foundational research, technological innovation, and industrial translation. She expressed optimism that the company will leverage its international team and platform advantages to accelerate the translation of original scientific breakthroughs into clinical applications.
Peptides referenced: Amylin.
Related reading: Torrey Pines Medicine Raises Funding For Ultra-Long-Acting Metabolic Therapies - Pulse 2.0, Turning Back the Clock: Why St. Johns County Patients Are Choosing Physician-Led Peptide Therapy, REX Files for New Peptide ETF as Peptide Boom Draws Investors, GLP-1 drugs Ozempic and Wegovy linked to higher hair loss risk.